Lu Dai, MD

Research Program: Cancer Biology Faculty Rank: Associate staff scientist Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Pathology

Cancer Research Interest

• Disease Site Focus: Leukemia/ Lymphoma, Breast
• Research Focus Area: Treatment
• Type of Research: Basic
• Research Interest Statement: My major interest is to identify cancer stem cells (CSCs) in different type of cancers, explore molecule mechanisms of CSCs in cancer progression and develop new strategies against CSCs.

Contact Information

• Email Address: LDAI@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• US Department of Defense – HT94252310083
  “Development of O'PROTACs-based Novel EIF4G1 Degrad”
  Co-Investigator
  01/15/23 – 01/14/24
• NIH/Nat. Inst. of Dental & Craniofacial Research – 1R03DE031978
  “Targeting ILlRAP in virus-associated malignancies”
  Principal Investigator
  05/01/22 – 04/30/24

Publications

• Chen J, Song J, Plaisance-Bonstaff K, [et al., including Dai L]. Role of Histamine and Related Signaling in Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis and Oncogenesis. Viruses. 2023 15(4). PMID: 37112991. PMCID: PMC10142667.
• Chen J, Wang Z, Phuc T, [et al., including Dai L]. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLoS pathogens. 2023 19(1):e1011089. PMID: 36638143. PMCID: PMC9879403.
• Chen J, Song J, Dai L, [et al.]. SARS-CoV-2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?. Journal of medical virology. 2022. PMID: 35819034. PMCID: PMC9350099.
• Chen J, Barrett L, Lin Z, [et al., including Dai L]. Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. Journal of cellular and molecular medicine. 2022. PMID: 35318805. PMCID: PMC9077304.
• Chen J, Dai L, Kendrick S, [et al.]. The anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesviruses Reactivation through Regulation of Intracellular Signaling Pathways. Antimicrobial agents and chemotherapy. 2022:aac0239521. PMID: 35041508. PMCID: PMC8923226.
• Dai L, Lu YC, Chen J, [et al.]. Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients. Frontiers in microbiology. 2022 13:882520. PMID: 35516440. PMCID: PMC9063630.
• Chen J, Song J, James J, [et al., including Dai L]. Activation of IL1 signaling molecules by Kaposi's sarcoma-associated herpesvirus. Frontiers in cellular and infection microbiology. 2022 12:1049624. PMID: 36457850. PMCID: PMC9705745.
• Chen J, Dai L, Barrett L, [et al.]. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Communications biology. 2021 4(1):682. PMID: 34083759. PMCID: PMC8175744.
• Del Valle L, Dai L, Lin HY, [et al.]. Role of EIF4G1 network in non-small cell lung cancers (NSCLC) cell survival and disease progression. Journal of cellular and molecular medicine. 2021. PMID: 33539648. PMCID: PMC7957206.
• Barrett L, Dai L, Wang S, Qin Z. Kaposi's sarcoma-associated herpesvirus and extracellular vesicles. Journal of medical virology. 2021. PMID: 33415746.
• Chen J, Dai L, Barrett L, [et al.]. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. bioRxiv : the preprint server for biology. 2020. PMID: 33024968. PMCID: PMC7536871.
• Dai L, Jung BG, Chen J, [et al.]. The potential impacts of early secreted antigenic target of 6 kDa (ESAT-6) of Mycobacterium tuberculosis on KSHV-infected cells. Journal of medical virology. 2020. PMID: 32648938. PMCID: PMC7796979.
• Chen J, Goyal N, Dai L, [et al.]. Developing new ceramide analogs and identifying novel sphingolipid controlled genes against a virus-associated lymphoma. Blood. 2020. PMID: 32518949. PMCID: PMC7645984.
• Chen J, Lin Z, Barrett L, [et al., including Dai L]. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG). Bioorganic chemistry. 2020 99:103847. PMID: 32311581. PMCID: PMC7260728.
• Dai L, Forrest J, Barrett L, [et al.]. Porphyromonas gingivalis coinfects with KSHV in oral cavities of HIV+ patients and induces viral lytic reactivation. Journal of medical virology. 2020. PMID: 32436999. PMCID: PMC7679274.
• Dai L, Forrest J, Qiao J, [et al.]. Kaposi Sarcoma-Associated Herpesvirus and Staphylococcus aureus Coinfection in Oral Cavities of HIV-Positive Patients: A Unique Niche for Oncogenic Virus Lytic Reactivation. The Journal of infectious diseases. 2020 221(8):1331-1341. PMID: 31111897. PMCID: PMC7325796.
• Barrett L, Chen J, Dai L, [et al.]. Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis. Frontiers in cellular and infection microbiology. 2020 10:587929. PMID: 33194830. PMCID: PMC7662392.
• Dai L, Chen J, Lin Z, [et al.]. Targeting Sphingosine Kinase by ABC294640 against Diffuse Intrinsic Pontine Glioma (DIPG). Journal of Cancer. 2020 11(16):4683-4691. PMID: 32626514. PMCID: PMC7330698.
• Chen J, Dai L, Goldstein A, [et al.]. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation. PLoS pathogens. 2019 15(12):e1008156. PMID: 31790497. PMCID: PMC6907871.
• Dai L, Del Valle L, Miley W, [et al.]. Transactivation of human endogenous retrovirus K (HERV-K) by KSHV promotes Kaposi's sarcoma development. Oncogene. 2018 37(33):4534-4545. PMID: 29743595. PMCID: PMC6195842.
• Qiao J, Cao Y, Zabaleta J, [et al., including Dai L]. Regulation of Virus-Associated Lymphoma Growth and Gene Expression by Bacterial Quorum-Sensing Molecules. Journal of virology. 2018 92(14). PMID: 29743366. PMCID: PMC6026753.
• Dai L, Smith CD, Foroozesh M, [et al.]. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. International journal of cancer. 2018 142(10):2153-2162. PMID: 29277894. PMCID: PMC5867242.
• Dai L, Chen J, Cao Y, [et al.]. Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth. Journal of Cancer. 2018 9(23):4503-4509. PMID: 30519356. PMCID: PMC6277659.
• Dai L, Zhao M, Jiang W, [et al.]. KSHV co-infection, a new co-factor for HPV-related cervical carcinogenesis?. American journal of cancer research. 2018 8(11):2176-2184. PMID: 30555737. PMCID: PMC6291645.
• Dai L, Qiao J, Del Valle L, Qin Z. KSHV co-infection regulates HPV16+ cervical cancer cells pathogenesis in vitro and in vivo. American journal of cancer research. 2018 8(4):708-714. PMID: 29736315. PMCID: PMC5934560.
• Dai L, Bai A, Smith CD, [et al.]. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth. Molecular cancer therapeutics. 2017 16(12):2724-2734. PMID: 28939554. PMCID: PMC5716930.
• Dai L, Lin Z, Jiang W, [et al.]. Lipids, lipid metabolism and Kaposi's sarcoma-associated herpesvirus pathogenesis. Virologica Sinica. 2017 32(5):369-375. PMID: 29019168. PMCID: PMC5869022.
• Dai L, Lin Z, Qiao J, [et al.]. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Oncogene. 2017 36(35):5068-5074. PMID: 28459467. PMCID: PMC5578886.
• Dai L, Lin Z, Cao Y, [et al.]. Targeting EIF4F complex in non-small cell lung cancer cells. Oncotarget. 2017 8(33):55731-55735. PMID: 28903455. PMCID: PMC5589694.
• Dai L, Cao Y, Jiang W, [et al.]. KSHV co-infection down-regulates HPV16 E6 and E7 from cervical cancer cells. Oncotarget. 2017 8(22):35792-35803. PMID: 28415759. PMCID: PMC5482618.
• Lam BQ, Dai L, Li L, [et al.]. Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma. Oncotarget. 2017 8(11):18373-18380. PMID: 28407694. PMCID: PMC5392335.
• Bonsignore L, Passelli K, Pelzer C, [et al., including Dai L]. A role for MALT1 activity in Kaposi's sarcoma-associated herpes virus latency and growth of primary effusion lymphoma. Leukemia. 2017 31(3):614-624. PMID: 27538487. PMCID: PMC5339436.
• Cao Y, Qiao J, Lin Z, [et al., including Dai L]. Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma. Oncotarget. 2017 8(9):15220-15229. PMID: 28146424. PMCID: PMC5362481.
• Lam BQ, Dai L, Qin Z. The role of HGF/c-MET signaling pathway in lymphoma. Journal of hematology & oncology. 2016 9(1):135. PMID: 27923392. PMCID: PMC5141645.
• Dai L, Bai L, Lin Z, [et al.]. Transcriptomic analysis of KSHV-infected primary oral fibroblasts: The role of interferon-induced genes in the latency of oncogenic virus. Oncotarget. 2016 7(30):47052-47060. PMID: 27363016. PMCID: PMC5216923.